MX2022003074A - Anticuerpos anti-cd371, y usos de los mismos. - Google Patents
Anticuerpos anti-cd371, y usos de los mismos.Info
- Publication number
- MX2022003074A MX2022003074A MX2022003074A MX2022003074A MX2022003074A MX 2022003074 A MX2022003074 A MX 2022003074A MX 2022003074 A MX2022003074 A MX 2022003074A MX 2022003074 A MX2022003074 A MX 2022003074A MX 2022003074 A MX2022003074 A MX 2022003074A
- Authority
- MX
- Mexico
- Prior art keywords
- seq
- antigen
- antibodies
- amino acid
- acid sequence
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La materia en cuestión descrita en la presente provee anticuerpos o fragmentos de unión a antígenos de los mismos que se unen a CD371 y métodos para usar tales anticuerpos o fragmentos de unión a antígenos de los mismos; en ciertas modalidades, el anticuerpo o fragmento de unión a antígenos del mismo comprende una región variable de cadena pesada que comprende una secuencia de aminoácidos que es al menos aproximadamente 80%, al menos 85%, al menos aproximadamente 90%, al menos aproximadamente 95%, al menos aproximadamente 96%, al menos aproximadamente 97%, al menos aproximadamente 98%, al menos aproximadamente 99%, al menos aproximadamente 100% homóloga o idéntica a la secuencia de aminoácidos expuesta en SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: SEQ ID NO: 9, o SEQ ID NO: 11.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900118P | 2019-09-13 | 2019-09-13 | |
| US201962936913P | 2019-11-18 | 2019-11-18 | |
| PCT/US2020/050380 WO2021050857A1 (en) | 2019-09-13 | 2020-09-11 | Anti-cd371 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022003074A true MX2022003074A (es) | 2022-06-14 |
Family
ID=74866534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003074A MX2022003074A (es) | 2019-09-13 | 2020-09-11 | Anticuerpos anti-cd371, y usos de los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220195064A1 (es) |
| EP (1) | EP4028422A4 (es) |
| JP (1) | JP2022547718A (es) |
| KR (1) | KR20220069961A (es) |
| CN (1) | CN114641503A (es) |
| AU (1) | AU2020346886A1 (es) |
| BR (1) | BR112022004603A2 (es) |
| CA (1) | CA3154387A1 (es) |
| IL (1) | IL291280A (es) |
| MX (1) | MX2022003074A (es) |
| WO (1) | WO2021050857A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4373856A1 (en) * | 2021-07-20 | 2024-05-29 | ABL Bio Inc. | Anti-cll-1 antibodies and uses thereof |
| WO2024107646A1 (en) | 2022-11-14 | 2024-05-23 | Caribou Biosciences, Inc. | Anti-cll-1 chimeric antigen receptors, engineered cells and related methods |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005000894A2 (en) * | 2003-06-25 | 2005-01-06 | Crucell Holland B.V. | Binding molecules for the treatment of myeloid cell malignancies |
| ES2679994T3 (es) * | 2005-08-11 | 2018-09-03 | Arpi Matossian-Rogers | Péptidos relacionados con TCR-V-BETA para el tratamiento y diagnóstico de enfermedad autoinmune |
| EP2975057A1 (en) * | 2006-07-10 | 2016-01-20 | Fujita Health University | Novel anti-cd73 antibody |
| PT2188313T (pt) * | 2007-08-21 | 2017-12-12 | Amgen Inc | Proteínas de ligação ao antigénio c-fms humano |
| JO3756B1 (ar) * | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| LT2809681T (lt) * | 2012-01-31 | 2019-02-11 | Regeneron Pharmaceuticals, Inc. | Antikūnai prieš asic1 ir jų panaudojimas |
| US9163090B2 (en) * | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| WO2016069549A1 (en) * | 2014-10-28 | 2016-05-06 | Albert Einstein College Of Medicine, Inc. | Multi-specific antibodies for cross-neutralization of multiple filovirus glycoproteins |
| WO2015174978A1 (en) * | 2014-05-15 | 2015-11-19 | R-Pharm Overseas, Inc. | Antibodies against human receptor integrin alpha-4 |
| US10501553B2 (en) * | 2014-11-19 | 2019-12-10 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for cancer treating conditions relating to over expressions of EphA2 |
| EA201890028A1 (ru) * | 2015-07-10 | 2018-08-31 | Мерус Н.В. | Антитело, связывающее cd3 человека |
| WO2017058944A1 (en) * | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors |
| EP3380524A4 (en) * | 2015-11-24 | 2019-07-24 | Cellerant Therapeutics, Inc. | HUMANIZED ANTI-CLL-1 ANTIBODIES |
| EP3555625A1 (en) * | 2016-12-16 | 2019-10-23 | Merck Patent GmbH | Methods for the use of galectin 3 binding protein detected in the urine for monitoring the severity and progression of lupus nephritis |
-
2020
- 2020-09-11 BR BR112022004603A patent/BR112022004603A2/pt unknown
- 2020-09-11 MX MX2022003074A patent/MX2022003074A/es unknown
- 2020-09-11 JP JP2022516402A patent/JP2022547718A/ja active Pending
- 2020-09-11 CA CA3154387A patent/CA3154387A1/en active Pending
- 2020-09-11 KR KR1020227012176A patent/KR20220069961A/ko unknown
- 2020-09-11 AU AU2020346886A patent/AU2020346886A1/en active Pending
- 2020-09-11 WO PCT/US2020/050380 patent/WO2021050857A1/en unknown
- 2020-09-11 CN CN202080077194.9A patent/CN114641503A/zh active Pending
- 2020-09-11 EP EP20863987.2A patent/EP4028422A4/en active Pending
-
2022
- 2022-03-10 IL IL291280A patent/IL291280A/en unknown
- 2022-03-11 US US17/692,979 patent/US20220195064A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114641503A (zh) | 2022-06-17 |
| US20220195064A1 (en) | 2022-06-23 |
| WO2021050857A1 (en) | 2021-03-18 |
| IL291280A (en) | 2022-05-01 |
| KR20220069961A (ko) | 2022-05-27 |
| BR112022004603A2 (pt) | 2022-08-02 |
| EP4028422A1 (en) | 2022-07-20 |
| WO2021050857A8 (en) | 2021-05-27 |
| AU2020346886A1 (en) | 2022-04-14 |
| EP4028422A4 (en) | 2024-01-10 |
| CA3154387A1 (en) | 2021-03-18 |
| JP2022547718A (ja) | 2022-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551930A1 (en) | Anti-sirpa antibodies and methods of use thereof | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| NZ598202A (en) | High affinity human antibodies to human angiopoietin-2 | |
| NZ623319A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| WO2022204316A3 (en) | Variant nucleic acid libraries for cd3 | |
| AU2015287227A8 (en) | Immune-stimulating monoclonal antibodies against human interleukin-2 | |
| NZ594682A (en) | Fully human antibodies specific to cadm1 | |
| CR20220646A (es) | Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos | |
| MX2022001111A (es) | Anticuerpo anti-pd-1 y uso farmaceutico del mismo. | |
| PH12018502293A1 (en) | Humanized anti-basigin antibodies and the use thereof | |
| MX2022007231A (es) | Anticuerpos anti-mertk y metodos de uso de los mismos. | |
| MX2020013324A (es) | Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos. | |
| MX2022001260A (es) | Anticuerpos anti-ms4a4a y metodos de uso de los mismos. | |
| JOP20210286A1 (ar) | جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr | |
| MX2022003074A (es) | Anticuerpos anti-cd371, y usos de los mismos. | |
| MX2024001067A (es) | Composicion farmaceutica y uso. | |
| ZA202205288B (en) | Humanized antibody and method for using the same | |
| PE20240589A1 (es) | ANTICUERPOS CD1a Y SU USO | |
| MX2021004976A (es) | Anticuerpo fn14 antihumano. | |
| MX2021014882A (es) | Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa. | |
| MX2023004713A (es) | Anticuerpo anti-cd73 y uso del mismo. | |
| MX2021014885A (es) | Composiciones de anticuerpos anti-tnf, y métodos para el tratamiento de la artritis psoriásica. | |
| MX2022001604A (es) | Anticuerpos anti bdca-2. | |
| MX2021008537A (es) | Composiciones de anticuerpos anti-tnf y métodos para el tratamiento de la artritis idiopática juvenil. | |
| EA202193325A1 (ru) | Композиции антител к фно для применения в способах лечения псориатического артрита |